The Phase 3 failure of semaglutide in Alzheimer’s disease highlights challenges in repurposing GLP-1 agonists, urging a shift towards biomarker-driven and personalized approaches in neurodegener...
Recent evidence shows moderate walking reduces tau buildup and inflammation, slowing Alzheimer’s progression. Epidemiological studies highlight dose-response benefits for accessible preventive h...
